These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 22113345)

  • 21. A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers.
    Radziszewski W; Lai E; Lazarus Shipitofsky N; Stroh M; Dishy V; Han L; Lewis W; Johnson-Levonas AO; Lutz R; Wagner J
    Am J Ther; 2010; 17(1):8-16. PubMed ID: 20027105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study.
    Morganroth J; Gretler DD; Hollenbach SJ; Lambing JL; Sinha U
    Expert Opin Pharmacother; 2013 Jan; 14(1):5-13. PubMed ID: 23216423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants.
    Zhang X; Jordan P; Cristea L; Salgo M; Farha R; Kolis S; Lee LS
    J Clin Pharmacol; 2012 Apr; 52(4):520-9. PubMed ID: 21558456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QT(c) interval in healthy volunteers.
    Taubel J; Naseem A; Wang D; Arezina R; Lorch U; Camm AJ
    Br J Clin Pharmacol; 2012 Aug; 74(2):296-303. PubMed ID: 22283848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil.
    Fossa AA; Langdon G; Couderc JP; Zhou M; Darpo B; Wilson F; Wallis R; Davis JD
    Clin Pharmacol Ther; 2011 Sep; 90(3):449-54. PubMed ID: 21814193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals.
    March B; Cardi T
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1807-15. PubMed ID: 19938897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
    Lincoff AM; Tardif JC; Neal B; Nicholls SJ; Rydén L; Schwartz GG; Malmberg K; Buse JB; Henry RR; Wedel H; Weichert A; Cannata R; Grobbee DE
    Am Heart J; 2013 Sep; 166(3):429-34. PubMed ID: 24016490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
    Stirban AO; Andjelkovic M; Heise T; Nosek L; Fischer A; Gastaldelli A; Herz M
    Diabetes Obes Metab; 2016 Jul; 18(7):711-5. PubMed ID: 26663152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of vardenafil and sildenafil on cardiac repolarization.
    Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
    Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
    Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.
    Démolis JL; Kubitza D; Tennezé L; Funck-Brentano C
    Clin Pharmacol Ther; 2000 Dec; 68(6):658-66. PubMed ID: 11180026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis.
    Han CL; Qu CZ
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):351-357. PubMed ID: 31929323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
    Lecka-Czernik B
    IDrugs; 2010 Nov; 13(11):793-801. PubMed ID: 21046527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
    Milic M; Bao X; Rizos D; Liu F; Ziegler MG
    Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
    Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
    Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
    Ruilope L; Hanefeld M; Lincoff AM; Viberti G; Meyer-Reigner S; Mudie N; Wieczorek Kirk D; Malmberg K; Herz M
    BMC Nephrol; 2014 Nov; 15():180. PubMed ID: 25407798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
    Foley-Comer AJ; Young AM; Russell-Yarde F; Jordan P
    Expert Opin Investig Drugs; 2011 Jan; 20(1):3-12. PubMed ID: 21114416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested.
    Zhang X; Silkey M; Schumacher M; Wang L; Raval H; Caulfield JP
    J Clin Pharmacol; 2009 May; 49(5):534-9. PubMed ID: 19287043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
    Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
    Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.
    Chen Y; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y; Qian J
    Diab Vasc Dis Res; 2017 Mar; 14(2):152-162. PubMed ID: 28111985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.